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INTRODUCTION
Chronic kidney disease (CKD) is widely prevalent in the 
United States, with a rate of 16.8% in adults over the age 
of 20 (MMWR Weekly, 2007). It has been associated with 
significantly increased all-cause and cardiovascular mortal-
ity (Tonelli et al., 2006). The disease predisposes patients 
to significant alteration in mineral and bone metabolism, 
which is now known as mineral and bone disorder (CKD-
MBD). CKD-MBD starts early during the course of CKD and 
becomes increasingly prevalent as the disease progresses 
(Martin et al., 2007). CKD-MBD has been well recognized as 
a risk factor for increased morbidity, hospitalization, all-cause 
mortality, and cardiovascular mortality among CKD and end-
stage renal disease (ESRD) patients (Block, Hulbert-Shearon, 
Levin, & Port, 1998; Ganesh, Stack, Levin, Hulbert-Shearon, 
& Port, 2001; Tentori et al., 2008; Wald et al., 2008). Studies 
conducted so far have primarily focused on prevalent ESRD 
patients (Table 1) regarding MBD markers and achievement 
of Kidney Disease Outcome Quality Initiative (K/DOQI) tar-
gets (Block et al., 1998; Young et al., 2004; Yokoyama et al., 
2004; Al Aly, Gonzalez, Martin, & Gellens, 2004; Maduell, 
Gorriz, Pallardo, Pons, & Santiago, 2005; Mahdavi-Mazdeh, 
Zamyadi, Norouzi, & Heidary Rouchi, 2007). Only a few 
studies on CKD-MBD markers have targeted the incident 
ESRD population (Tangri et al., 2011; Danese, Belozeroff, 
Smirnakis, & Rothman, 2008; Melamed et al., 2006), but 
data on minority patients are lacking. Minorities receive less 
pre-ESRD care and are more likely to be initiated on main-
tenance dialysis at more-advanced stages of CKD. Because 
Center for Medicare and Medicaid Services (CMS) Medical 
Evidence Form 2728 for incident ESRD patients does not 
require reporting of CKD-MBD indicators, complete data 
on MBD status in minority incident patients remain inacces-
sible. We conducted a retrospective cross-sectional study 
to determine the MBD status of minority incident ESRD 
patients.
METHODS
We conducted a retrospective observational study on 174 
incident ESRD patients who initiated hemodialysis at the 
Lincoln Medical and Mental Health Center hemodialy-
sis unit between January 2000 and September 2008. Our 
hemodialysis unit, serving a predominantly minority popula-
tion, is an inner-city, hospital-based unit; all patients were 
started on dialysis in the hospital. Patients’ baseline data 
were collected from CMS Medical Evidence Form 2728 and 
electronic medical records. Laboratory data from within 15 
days of the initiation of dialysis were collected. Patients fol-
lowed for less than three months after dialysis initiation were 
excluded because of the possibility of renal recovery during 
that period.
It was our standard practice to check for MBD markers at 
or prior to initiation of hemodialysis. Calcium level was cor-
rected for serum albumin using the formula of observed 
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calcium + 0.8 x (4.0 - serum albumin [g/dL]). Corrected 
calcium was used to calculate calcium-phosphorus prod-
uct. Glomerular filtration rate (GFR) was estimated with 
the modification of diet in renal disease formula (Levey et 
al., 1999). Target values of MBD markers for CKD stage 5 
were established per K/DOQI guidelines (calcium 8.4–9.5 
mg/dL, phosphorus 3.5–5.5 mg/dL, calcium-phosphorus 
product less than 55 mg2/dL2, and intact parathyroid hor-
mone [iPTH] 150–300 pg/mL) (K/DOQI Clinical Practice 
Guidelines, 2003).
Statistical Analysis
Data were analyzed using a two-tailed Student’s t-test, chi 
square test, logistic regression analysis, and analysis of 
variance (ANOVA). A p-value of less than 0.05 was consid-
ered statistically significant. We also analyzed the trend of 
achievement of target CKD-MBD marker values between 
the years 2000 and 2008 by dividing the time period into 
two-year intervals. We attempted to assess the impact of 
the K/DOQI guidelines publication in our study population. 
All analyses were performed with Stata Version 11.2 (Stata 
Corp., Odessa, TX). The study protocol was reviewed and 
approved by our Institutional Review Board.
 
RESULTS
One hundred seventy-four patients were included in the 
study, with a mean age of 53.7±16.1 years, mean body 
mass index (BMI) of 26.67±5.98 kg/m2, and mean estimated 
Table 1 | National and International Experiences in Prevalent ESRD Patients Regarding CKD-MBD Markers
CKD Stage 5 Target 
Values
DOPPS I (1998) DOPPS II 
(2004)
Yokoyama et 
al. (2004)
Al Aly et al. 
(2004)
Maduell et al. 
(2005)
Mahdavi-
Mazdeh et al. 
(2007)
Calcium (8.4–9.5 mg/
dL) 40.5% 42.5% 49% 49% 45% 53.2%
Phosphorus (3.5–5.5 
mg/dL) 40.8% 44.4% 50% 36% 55% 52.2%
Calcium x 
Phosphorus (<55 
mg2/dL2)
56.5% 61.4% — 57% 73% 75.1%
iPTH (150–300 pg/
mL) 21.4% 26.2% 27% 20% 26% 27.7%
All Four Target Values 
Met 4.6% 5.5% 9% 7% 7.3% 1.8%
Table 2 | Patients’ Baseline Characteristics
Our Study Population USRDS (2000–2006) p-value
Total Patients n=174 n=709,212 —
    Female 89 (51.1%) 45.4% 0.14
         Hispanic 116 (66.7%) 13.2% <0.0001
         African American 49 (28.1%) 28% 0.96
         Asian 9 (5.2%) 2.6% 0.05
Mean Age (years) 53.7±16.1 62.8 0.001
Mean eGFR (mL/min/1.73m2 ) 6.7±4.03 9.9 0.001
Mean BMI (kg/m2) 26.67±5.98 27.7 0.02
ESRD Etiology
      Diabetes Mellitus 39.1% 44.8% 0.14
      Hypertension 20.1% 27.4% 0.03
      Chronic Glomerulonephritis 19.5% 9.9% <0.0001
      HIV Nephropathy 3.4% 0.8% 0.0005
      Polycystic Kidney Disease 2.3% 2.2% 0.9
      Obstructive Uropathy 2.3% — —
      Other 13.3% 14.9% 0.6
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GFR (eGFR) of 6.7±4.03 mL/min/1.73m2. Hispanic, African 
American, and Asian ethnicity made up 66.7%, 28.1%, and 
5.2% of the studied patients respectively. Table 2 sum-
marizes patients’ baseline characteristics compared with 
United States Renal Data System (USRDS) incident ESRD 
patients from 2000 to 2006 (U.S. Renal Data System, 2008). 
Health coverage was as follows: Medicaid, 36%; Medicare, 
13%; both Medicaid and Medicare, 16%; other, 3%. Thirty-
two percent of patients were without any coverage. Most 
patients were unemployed (82%) or retired (11% due to age 
and 1% due to disability). 
Mean lab values with one standard deviation in incident 
ESRD patients were as follows: albumin 3.05±0.77 g/dL, 
calcium 8.5±1.3 mg/dL, phosphorus 5.5±2.2 mg/dL, iPTH 
440.9±397.8 pg/mL, and calcium-phosphorus product 
46.7±18.5 mg2/dL2. The impact of the K/DOQI guidelines 
was assessed as shown in Table 3. We compared mean val-
ues of CKD-MBD markers before December 31, 2003, and 
after January 1, 2004 (three months after the guidelines 
were published in October 2003), and found no difference, 
aside from higher iPTH levels in the post-K/DOQI era. 
Figure 1 shows trends of proportions of patients achieving 
target CKD-MBD markers over eight years. Target value for 
the calcium-phosphorus product was achieved in 65% to 
77% of the patients, whereas the other CKD-MBD marker 
targets were met in only 28% to 45% of the patients. Logistic 
regression analysis showed trends to be nonsignificant for 
all values. Similarly, trends of CKD-MBD marker mean values 
over the years were nonsignificant as analyzed by ANOVA 
(Figures 2A–C).
The target calcium value was met in 34% of the patients, 
while 45% of the patients had calcium less than 8.4 mg/dL 
and 21% of the patients had calcium greater than 9.5 mg/
dL. The target value of phosphorus was met in 42% of the 
patients, while 16% of the patients had phosphorus less than 
3.5 mg/dL and 42% of the patients had phosphorus greater 
than 5.5 mg/dL. Seventy-two percent of the patients had 
calcium-phosphorus product in the target range, while 28% 
of the patients had an elevated calcium-phosphorus prod-
uct of greater than 55 mg2/dL2. The target iPTH level was 
met in 31% of the patients, while an iPTH level of   <150 pg/
mL was seen in 17% of the patients. An elevated iPTH level 
of greater than 300 pg/mL was seen in 52% of the patients. 
Only 6% of the patients met all four target values. Age, 
gender, ethnicity, and BMI did not have a statistically signifi-
cant impact on the achievement of target CKD-MBD marker 
values, except that patients with calcium within the target 
range were significantly older than patients with calcium 
less than 8.4 mg/dL (57.5±17.9 years vs. 51.3±14.9 years, 
p-value = 0.03).
DISCUSSION
Results of our study showed that there were no significant 
changes in the trends of CKD-MBD markers and the propor-
tion of patients achieving target values in minority incident 
ESRD patients over the years of our study. The introduction 
of the K/DQOI guidelines also did not result in significant 
improvement in mean values of CKD-MBD markers; we 
found significantly higher iPTH values after the publication 
of the guidelines.
Our patients were significantly younger compared with the 
national average and had lower eGFR at initiation of dialysis 
and lower BMI, but they also had a significantly higher pro-
portion of HIV nephropathy and chronic glomerulonephritis 
as the etiology of ESRD. Lower eGFR at dialysis initiation 
likely reflects late presentation for medical care in our popu-
lation. The remaining comorbidities were comparable. 
Our study population consists predominantly of minori-
ties and is considerably different from the USRDS popula-
tion, with a significantly higher proportion of Hispanics. 
Minorities constitute about one third of the U.S. population, 
with Hispanics being the largest minority group. Minority 
populations tend to be poorer and have less education, and 
Table 3 | Mean Values of CKD-MBD Markers in Pre- and Post-K/DOQI Guidelines
MBD Markers Pre-K/DOQI Post-K/DOQI p-value
Calcium (mg/dL) 8.6±1.2 8.4±1.3 0.2
Phosphorus (mg/dL) 5.4±2.2 5.7±2.1 0.28
iPTH (pg/mL) 377±307 523±480 0.01
Calcium x Phosphorus (mg2/dL2) 45.7±19 47.4±17.8 0.55
2000-01 2002-03 2004-05
Ca
Phos
PTH
Ca x P
2006-08
90
80
70
60
50
40
30
20
10
0
Figure 1 | Percentage of patients achieving CKD-MBD targets. 
p > 0.05 (nonsignificant) for all trends
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they are more likely to lack health insurance coverage and 
to suffer from a severe disease burden. These factors could 
be significant barriers to obtaining appropriate healthcare 
in our patient population. According to 2011 U.S. Census 
Bureau data, 30.1% of Hispanics and 19.5% of blacks were 
without health insurance (U.S. Census Bureau, 2011). Eighty-
two percent of our patients were unemployed, and 32% of 
our patients were without any medical coverage. According 
to the USRDS, in 2005–2007, 20.2% of incident ESRD 
patients were unemployed and 7.6% were without health 
insurance (U.S. Renal Data System, 2012). MBD is widely 
prevalent in minority incident ESRD patients, which could 
be due to lack of pre-ESRD care and lack of health insur-
ance, and may be related to unemployment, poor socioeco-
nomic status, or poverty.
Nephrologists have to complete CMS Medical Evidence 
Form 2728 upon initiation of maintenance dialysis. The 
requested information includes all demographic data, 
comorbid conditions, and laboratory values except CKD-
MBD markers. Thus, the nationwide prevalence of CKD-MBD 
abnormalities at initiation of dialysis remains undetermined. 
Only recently have CMS guidelines mandated monitoring of 
CKD-MBD markers in ESRD patients.
To our knowledge, ours is the first study reporting the sta-
tus of mineral and bone metabolism markers and achieve-
ment of target values in minority incident ESRD patients. 
Dialysis Outcomes and Practice Patterns Study (DOPPS) 
data reported on the achievement of target values for CKD-
MBD in prevalent ESRD patients only (Mahdavi-Mazdeh et 
al., 2007).
According to DOPPS II data, target calcium, phosphorus, 
calcium-phosphorus product, and iPTH values were met 
in 42.5%, 44.4%, 61.4%, and 26.2% of prevalent ESRD 
patients, respectively, in the United States. These targets 
were met in 34%, 42%, 72%, and 31% of incident ESRD 
patients, respectively, in our study population. All four tar-
gets were met in only 5.5% of DOPPS II prevalent ESRD 
and 6% of our incident ESRD patients. It should be noted 
that these comparisons are not among similar patient popu-
lations, as these similar proportions of patients achieving 
target CKD-MBD marker values represent widely heteroge-
neous ESRD subsets in each study group.
Major features of deranged mineral and bone metabo-
lism include hypocalcaemia, hyperphosphatemia, second-
ary hyperparathyroidism, altered Vitamin D metabolism, 
bone disease, soft-tissue calcification (including coronary 
artery and cardiac valves), pruritus, proximal myopathy, 
calciphylaxis, skin ulceration, and soft-tissue necrosis (K/
DOQI Clinical Practice Guidelines, 2003). Abnormalities in 
arterial stiffness have been shown to be important media-
tors of cardiovascular events in patients with CKD (Block & 
Port, 2003). Hyperphosphatemia is associated with higher 
fracture risk (Block et al., 2004), increased pulse pressure 
(Klassen et al., 2002), increased risk of all-cause mortality 
(Ganesh et al., 2001; Wald et al., 2008; Block et al., 2004), 
cardiovascular mortality (Block et al., 1998; Ganesh et al., 
Figure 2 | Trends of levels of CKD-MBD markers. (A) Trends of 
levels of calcium and phosphorus. (A-C) P > 0.05 (nonsignificant) 
for all trends. (B) Trends of levels of calcium x phosphorus product . 
(C) Trends of levels of iPTH.
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2001; Young et al., 2005), infection-related mortality, and 
sudden death (Ganesh et al., 2001). 
An analysis of the United Kingdom Renal Registry by Tangri 
et al. (2011) including incident ESRD patients between 
January 2002 and December 2004 showed target achieve-
ment among patients for calcium (43–47%), phosphorus 
(54–62%), and iPTH (23-26% ), and did not find a benefit 
of achievement of K/DOQI targets in decreasing all-cause 
mortality. In contrast, the study by Danese et al. (2008) of 
incident ESRD patients between July 2000 and June 2002 
showed consistent achievement of CKD-MBD targets to be 
a strong predictor of survival. 
Block et al. (2004) showed population-attributable risk of all-
cause mortality in CKD stage 5 to be 17.5% for MM mineral 
metabolism abnormalities (phosphorus greater than 5.0 mg/
dL, calcium greater than 10 mg/dL, iPTH greater than 600 
pg/mL), 11.3% for anemia (hemoglobin less than 11 gm/
dL), and 5.1% for insufficient dialysis (urea reduction ratio 
less than 65%). Their study highlights the impact of mineral 
and bone metabolism disorders on mortality in advanced 
CKD compared with anemia and inadequate dialysis, which 
was the main focus until recently. Presently, the beneficial 
effect of achieving CKD-MBD markers is demonstrated only 
by observational studies. Various organizations around the 
world set forth guidelines for MBD in advanced CKD that 
were most recently updated by KDIGO (Kidney Disease: 
Improving Global Outcomes) in 2009. 
Our study cohort differs in racial and ethnic makeup from 
the overall ESRD population of the United States. However, 
this difference has the potential to highlight disparities in 
care among those at greatest risk for complications because 
of socioeconomic factors. Our study had a small sample size 
and we lacked data on pre-ESRD care and outcomes such 
as mortality, which would have improved our understanding 
of the impact of achieving target CKD-MBD markers. We 
also lack information on the use of phosphate binders and 
vitamin D analogues in our study population.
CONCLUSION
Our study demonstrated that mineral and bone metabolism 
abnormalities are widely prevalent in minority incident ESRD 
patients, and only 6% of the patients achieved target val-
ues for all MBD markers at the time of initiation of dialysis. 
This finding may be explained by lack of pre-ESRD care in 
our minority population. Estimating CKD-MBD status at the 
initiation of dialysis and including MBD indicators on the 
CMS medical evidence form will help ascertain the magni-
tude of MBD in ESRD patients. Early referral to nephrology 
and early recognition and management of CKD-MBD as per 
the guidelines may affect morbidity and mortality related to 
these disorders.  
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